+47.6%
GSK vs RPRX
+123.5%
-75.8%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | RPRX | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | 0.0% | +0.2% | +0.2% |
| 7D | -3.6% | -4.0% | +0.4% | -2.3% |
| 30D | -5.9% | +4.9% | -10.9% | -7.4% |
| 3M | -4.3% | +9.4% | -13.6% | -7.1% |
| 6M | -10.8% | +33.3% | -44.1% | -18.6% |
| YTD | +1.8% | +59.0% | -57.2% | -11.5% |
| 1Y | +23.5% | +69.2% | -45.7% | +5.4% |
| All | +47.6% | +123.5% | -75.8% | +17.5% |
Cumulative growth
Daily Returns
Daily percentage return beside RPRX.
Daily Out/Under-Performance
Portfolio return minus RPRX return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × RPRX return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded RPRX wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling